Dr. Kumar’s Take:
This small trial gave preschoolers with viral-induced asthma two oral doses of 100,000 IU vitamin D3, one in the fall and one in the winter, and it did what a bolus is supposed to do: serum 25-hydroxyvitamin D rose fast and stayed safe. The limitation is durability. Ten days after each dose the separation from placebo was large, but by 3.5 and 7 months the group difference no longer reached statistical significance, and only slightly more than half of the children were still at 75 nmol/L or above. If the goal is sufficiency across a whole fall and winter, two boluses alone will not get most children there.
Key Takeaways:
✔ Two oral doses of 100,000 IU vitamin D3 given 3.5 months apart raised serum vitamin D rapidly in preschoolers with viral-induced asthma.
✔ The adjusted group difference in change from baseline was 57.8 nmol/L (95% CI 47.3 to 68.4), p < 0.0001, favouring vitamin D.
✔ At 3.5 and 7 months, 63% and 56% of the vitamin D group were sufficient (≥ 75 nmol/L), compared with 39% and 36% of the placebo group.
✔ Hypercalciuria, all without hypercalcaemia, appeared in 8.7% of intervention samples and 10.3% of control samples.
Actionable Tip:
If your child has asthma and lives at a northern latitude, ask your clinician about checking vitamin D status rather than assuming a seasonal dosing plan holds levels up. In this trial, two boluses were not enough to keep most children at 75 nmol/L or above through 7 months.
Study Summary: Vitamin D Boluses in Asthmatic Preschoolers
This was a 7-month, triple-blind, randomised, placebo-controlled pilot trial in children aged 1 to 5 years with viral-induced asthma. Forty-seven children were randomised in the fall, 23 to vitamin D and 24 to placebo. Each child received two oral doses of 100,000 IU vitamin D3 or identical placebo, 3.5 months apart, once in the fall and once in the winter. The main outcome was the change in serum 25-hydroxyvitamin D from baseline over time and at 3.5 and 7 months. Other outcomes included the proportion of children reaching 25OHD of 75 nmol/L or above, safety, and adverse event rates.
Study Design:
- Type: Triple-blind, placebo-controlled pilot RCT
- Duration: 7 months
- Participants: 47 preschool children aged 1 to 5 with viral-induced asthma
- Intervention: Two oral doses of 100,000 IU vitamin D3, 3.5 months apart
- Control: Identical placebo doses
- Main Outcome: Change from baseline in serum 25-hydroxyvitamin D (25OHD), measured by tandem mass spectrometry at baseline, 10 days, 3.5 months, 3.5 months plus 10 days, and 7 months
Results:
- The adjusted group difference in change from baseline was 57.8 nmol/L (95% CI 47.3 to 68.4), p < 0.0001, with a time effect (p < 0.0001) and a group by time interaction (p < 0.0001), favouring vitamin D.
- Ten days after the first bolus, the group difference in change from baseline was 119.3 nmol/L (95% CI 105.8 to 132.9); ten days after the second, it was 100.1 nmol/L (95% CI 85.7 to 114.6).
- At 3.5 and 7 months the group difference did not reach statistical significance.
- At 3.5 and 7 months, 63% and 56% of the vitamin D group were sufficient (≥ 75 nmol/L), versus 39% and 36% of the control group.
- Hypercalciuria, all without hypercalcaemia, occurred in 8.7% of intervention samples and 10.3% of control samples at any time point.
- Exacerbations requiring rescue oral corticosteroids occurred at a rate of 0.87 per child, and the authors identify that outcome as a promising primary endpoint for a full trial.
Why Vitamin D Matters for Asthmatic Kids
Asthma is the most common chronic disease of childhood, affecting about 10% of children, and preschoolers have the highest rate of emergency department visits of any age group. The authors note that new evidence supports supplemental vitamin D for preventing asthma exacerbations, but the dosing that raises serum levels enough while keeping adherence realistic has not been settled. This pilot was designed to test one such regimen, and it shows the ceiling of a bolus-only approach: rapid correction, incomplete maintenance.
Related Studies and Research
Global Prevalence of Vitamin D Deficiency: A Meta-Analysis: Maps worldwide deficiency rates to contextualize population risk.
Effect of Two 100 000 IU Vitamin D₃ Bolus Doses on Viral-Induced Asthma in Preschoolers: Pilot RCT evaluating high-dose vitamin D for asthma exacerbation prevention.
Study Revealing Obesity-Induced Suppression of CYP2R1 and Vitamin D Deficiency: Mechanistic insights into how obesity downregulates the 25-hydroxylase enzyme.
Role of Vitamin D and Calcium in Type 2 Diabetes Prevention: A Systematic Review and Meta-Analysis: Examines nutrient synergy on glycemic control and diabetes risk.
Vitamin D Status Modulates Mitochondrial Oxidative Capacity in Skeletal Muscle: Implications for Sarcopenia: Links 25(OH)D levels to muscle energy metabolism and age-related loss.
Frequently Asked Questions
Is 100,000 IU of vitamin D safe for kids?
In this pilot, the authors describe the regimen as raising serum vitamin D rapidly, safely, and significantly. Hypercalciuria without hypercalcaemia was seen in 8.7% of intervention samples, and in 10.3% of control samples, so it was not more common in the children who got vitamin D.
Does this help prevent asthma attacks?
This was a pilot trial designed to test the dosing, not to answer that question. Exacerbations requiring rescue oral corticosteroids occurred at a rate of 0.87 per child, and the authors flag that outcome as a promising primary endpoint for a larger trial.
Why not just take daily supplements?
The authors frame the open question as finding a dose that raises serum levels sufficiently while maximising adherence. A twice-yearly bolus is an attempt to solve the adherence half of that problem, and this trial tested how far it gets on the serum-level half.
Can I use this strategy with my child?
Check with a healthcare provider before giving high-dose vitamin D to a child. This was a pilot trial in 47 children, which is a starting point for a larger study rather than a basis for a dosing recommendation.
Conclusion
Two oral boluses of 100,000 IU vitamin D3, one in the fall and one in the winter, rapidly, safely, and significantly raised serum vitamin D metabolites in these preschoolers. But the regimen kept 25OHD at 75 nmol/L or above across 7 months in only slightly more than half of the children, and by 3.5 and 7 months the difference from placebo was no longer statistically significant. I read that as a dosing schedule that corrects a deficit quickly and then loses ground, which is exactly the kind of finding a pilot is meant to surface before a full trial is designed.
